Clinical trials: XLP

Parkinson's Disease

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

• Completed
• Age: 19 to 45 years
• Phase 1
• Results posted

This first in human, single-center, randomized, placebo-controlled, double blind, sequential group Phase 1 study in healthy subjects will be conducted to evaluate the safety, tolerability, PK, and PD following the escalation of…

Trial name

NCT03022799

Testing

KM-819

Where

South Korea

Volunteers

88 people, healthy volunteers welcome

Sponsor

Kainos Medicine Inc.